1998
DOI: 10.1021/jm980421f
|View full text |Cite
|
Sign up to set email alerts
|

Dual D2-Receptor and β2-Adrenoceptor Agonists for the Treatment of Airway Diseases. 1. Discovery and Biological Evaluation of Some 7-(2-Aminoethyl)- 4-hydroxybenzothiazol-2(3H)-one Analogues

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
20
0
1

Year Published

2004
2004
2018
2018

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 44 publications
(21 citation statements)
references
References 17 publications
0
20
0
1
Order By: Relevance
“…The development of a long-acting, dual D 2 -receptor and b 2 -adrenoceptor agonist as a novel treatment for chronic obstructive pulmonary disease (COPD) has highlighted the importance of specific drugYphospholipid membrane interactions (4,5). The duration of b 2 -adrenoceptor agonism has been found to correlate with the membrane affinity of compounds that possess either protonated or unprotonated secondary amino groups, at pH 7.4 (4); the former compounds are predominantly cationic, whereas the latter are predominantly electronically neutral.…”
Section: Introductionmentioning
confidence: 99%
“…The development of a long-acting, dual D 2 -receptor and b 2 -adrenoceptor agonist as a novel treatment for chronic obstructive pulmonary disease (COPD) has highlighted the importance of specific drugYphospholipid membrane interactions (4,5). The duration of b 2 -adrenoceptor agonism has been found to correlate with the membrane affinity of compounds that possess either protonated or unprotonated secondary amino groups, at pH 7.4 (4); the former compounds are predominantly cationic, whereas the latter are predominantly electronically neutral.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, in the therapy of airway diseases, dual dopamine D 2 receptors (D 2 )/␤ 2 -receptor agonists have been shown to have beneficial effects compared with conventional ␤ 2 -receptor agonists alone (4). Functional experiments indicate that this additional effect is mediated through normalizing the pathological increased activity of sensory nerves (17).…”
mentioning
confidence: 99%
“…The structures of a weak β 2 -adrenoceptor agonist (5.65) and a potent D 2 -receptor agonist (5.66) were hybridized to give 5.67. Modification of the side chain gave 5.68, [122] which went into clinical trials for the treatment of the symptoms of COPD.…”
Section: Dual-acting Drugs: Dual-acting Enzyme Inhibitorsmentioning
confidence: 99%